Shareholders Approve 5 Million Share Increase for Equity Incentive Plan
DFTX has more than doubled off its 52-week low of $6.345.
Summary
Definium Therapeutics shareholders approved an amendment to the 2025 Equity Incentive Plan, increasing the shares available for issuance by 5,000,000, which could lead to significant future dilution.
Key Events · Corporate Governance and Compliance · DFTX
-
Equity Plan Amendment Approved
Shareholders approved an amendment to the 2025 Equity Incentive Plan, increasing the number of common shares available for issuance by 5,000,000.
-
Increased Potential Dilution
The total number of shares authorized under the plan is now 14,500,000. If all authorized shares were issued, this would represent a potential dilution of approximately 13.29% based on current outstanding shares.
-
Routine Shareholder Approvals
Shareholders also re-elected seven directors to the Board and approved the appointment of KPMG LLP as the independent registered public accounting firm for the upcoming year.
Analysis · DFTX · Life Sciences
Shareholders have approved a significant increase in the number of common shares available for issuance under the company's 2025 Equity Incentive Plan. This authorization allows Definium Therapeutics to issue an additional 5,000,000 shares, primarily for employee compensation and incentives. While no shares have been sold yet, this approval creates substantial potential for future dilution for existing shareholders, as the total shares authorized under the plan now represent over 13% of current outstanding shares.
How filings like this one have moved
In the 30 days to Sep 15, 2026, 35.6% of the 1100 measured filings Wiseek scored 8 moved their stock by 5% or more by the next session's close. The median move was -0.43%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, DFTX was trading at $24.75 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $2.7B. The 52-week trading range was $6.35 to $26.25. This filing was assessed with negative market sentiment and an importance score of 8 out of 10.